The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
10,876
Sort by:
Herceptin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Herceptin ...
January 2019
35 pages
Humalog- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Humalog ...
January 2019
35 pages
Humatrope- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Humatrope ...
January 2019
35 pages
Humira- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Humira ...
January 2019
35 pages
Imitrex- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Imitrex ...
January 2019
35 pages
Imprida- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Imprida ...
January 2019
35 pages
Imusera- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Imusera ...
January 2019
35 pages
Integrilin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Integrilin ...
January 2019
35 pages
Intuniv- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Intuniv ...
January 2019
35 pages
Invanz- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Invanz ...
January 2019
35 pages
Iressa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Iressa ...
January 2019
35 pages
Isentress- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Isentress ...
January 2019
35 pages
Jalyn- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Jalyn ...
January 2019
35 pages
Jevtana Kit- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Jevtana Kit ...
January 2019
35 pages
Kaletra- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kaletra ...
January 2019
35 pages
Keppra- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Keppra ...
January 2019
35 pages
Kivexa- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Kivexa ...
January 2019
35 pages
Lamictal- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lamictal ...
January 2019
35 pages
Latuda- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Latuda ...
January 2019
35 pages
Loestrin 24 Fe- Drug Insight, 2019
US$ 1,000.00
... Coverage of the Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY ...
January 2019
35 pages
Lumigan RC- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lumigan ...
January 2019
35 pages
Lunesta- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lunesta ...
January 2019
35 pages
Lyrica- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Lyrica ...
January 2019
35 pages
Maxalt- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Maxalt ...
January 2019
35 pages
Merrem PWS IV- Drug Insight, 2019
US$ 1,000.00
... Coverage of the Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY ...
January 2019
35 pages
Metgluco- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Metgluco ...
January 2019
35 pages
Methycobal Tablets- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Methycobal Tablets ...
January 2019
35 pages
Mezavant Xl- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mezavant ...
January 2019
35 pages
Minerva-35- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Minerva ...
January 2019
35 pages
Mucodyne- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mucodyne ...
January 2019
35 pages
Mucosta- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mucosta ...
January 2019
35 pages
Multaq- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Multaq ...
January 2019
35 pages
Mycamine- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Mycamine ...
January 2019
35 pages
Myfortic- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Myfortic ...
January 2019
35 pages
Namenda- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Namenda ...
January 2019
35 pages
Nebivololo Mylan- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nebivololo Mylan ...
January 2019
35 pages
Nesina- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nesina ...
January 2019
35 pages
Neurontin- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Neurontin ...
January 2019
35 pages
Nexavar- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexavar ...
January 2019
35 pages
Nexium-Mups- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexium-Mups ...
January 2019
35 pages
Nexplanon- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nexplanon ...
January 2019
35 pages
Niaspan LP- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Niaspan ...
January 2019
35 pages
Norvasc- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Norvasc ...
January 2019
35 pages
Norvir SEC- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Norvir SEC ...
January 2019
35 pages
Novothyrox- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Novothyrox ...
January 2019
35 pages
Nuvaring- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuvaring ...
January 2019
35 pages
Nuvigil- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Nuvigil ...
January 2019
35 pages
Onglyza- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Onglyza ...
January 2019
35 pages
Onitsit- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Onitsit ...
January 2019
35 pages
Opana ER- Drug Insight, 2019
US$ 1,000.00
... Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2019-2021 Market competition and emerging therapies SWOT Analysis REASONS TO BUY Establish a comprehensive understanding of Opana ...
January 2019
35 pages
